GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Praxis Precision Medicines
Praxis Precision Medicines is a biotech company focused on treating neurological disorders. Its stock price is highly volatile and depends on the results of clinical trials of its drugs targeting complex diseases of the central nervous system.
Share prices of companies in the market segment - Neuro
Praxis is a biotech company specializing in the treatment of neurological disorders. We classify it as part of the Neuro sector, and the chart below reflects the dynamics of this entire segment, driven by news about clinical trials and regulatory decisions.
Broad Market Index - GURU.Markets
Praxis Precision Medicines is a biopharmaceutical company developing drugs to treat central nervous system disorders such as epilepsy and depression. As a component of the GURU.Markets index, it represents the neuroscience sector. The chart below represents the entire market. See how Praxis shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
PRAX - Daily change in the company's share price Praxis Precision Medicines
For Praxis Precision Medicines, a biopharmaceutical company, change_co is a measure of the sector's inherent high volatility. Each daily change reflects sensitivity to news about clinical trials of its drugs. This metric isn't just noise, but a critical component of the models on System.GURU.Markets that assess neuroscience risk.
Daily change in the price of a set of shares in a market segment - Neuro
Praxis Precision Medicines, Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with PRAX, which focuses on CNS diseases, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Praxis is a biopharmaceutical company specializing in drugs for the treatment of diseases of the central nervous system. Neuroscience is a risky area of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with Praxis's developments.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Praxis Precision Medicines
Praxis is a biotech company working on treatments for neurological diseases. Its shares represent a venture-backed bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the overall stock market.
Annual dynamics of market capitalization of the market segment - Neuro
Praxis Precision Medicines, Inc. is a clinical-stage biotech company developing drugs for the treatment of neurological disorders. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this complex area of medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Praxis Precision is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Praxis Precision Medicines
Praxis, a biopharmaceutical company, has a speculative market cap. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its neurological drugs, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Neuro
Developing drugs for the central nervous system is one of the most complex challenges in biotechnology. The dynamics of this sector, as shown in the chart, reflect a high degree of risk and volatility. In this environment, companies like Praxis Precision Medicines are pursuing new treatments.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Praxis Precision Medicines, a biopharmaceutical company focused on neuroscience, operates by the laws of science. Its stock price is driven by research results, not market cycles. Its performance is completely disconnected from general economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Praxis Precision Medicines
Shares of Praxis, a biopharmaceutical company focused on treating neurological disorders, experience high volatility on a weekly basis. Any news about the progress of clinical trials, especially for rare types of epilepsy, provokes a sharp reaction from investors.
Weekly dynamics of market capitalization of the market segment - Neuro
Praxis Precision Medicines shares, like the entire neuroscience biotech sector, are driven by overall investor sentiment and news of breakthroughs. The success or failure of one major study can impact the entire industry. The chart shows how the company fares against this volatile backdrop.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Praxis, like many biotech companies, can exhibit dynamics completely unrelated to the market. Positive clinical trial data can cause its shares to skyrocket even on the day the S&P 500 is plunging. The chart will show these moments of "living in its own world."
Market capitalization of the company, segment and market as a whole
PRAX - Market capitalization of the company Praxis Precision Medicines
Praxis Precision Medicines' market cap is the financial valuation of a biotech company focused on treating rare neurological diseases such as epilepsy. The chart reflects investor expectations for its scientific platform. Its speculative dynamics tell the story of how the market evaluates the potential of clinical trials in a complex and understudied field.
PRAX - Share of the company's market capitalization Praxis Precision Medicines within the market segment - Neuro
Praxis Precision Medicines is a biotech company focused on treating neurological disorders by modulating ion channels in the brain. Its market share is based on this cutting-edge approach. The chart shows how the market assesses its chances of developing breakthrough drugs for epilepsy and other CNS disorders.
Market capitalization of the market segment - Neuro
Praxis Precision Medicines develops drugs to treat central nervous system disorders using a genetic approach. The chart below shows the overall market capitalization of the neuroscience sector. It reflects the hope that genetics will hold the key to treating epilepsy and other serious illnesses.
Market capitalization of all companies included in a broad market index - GURU.Markets
Treating neurological diseases is one of the most challenging biotech challenges, as seen in the chart. Praxis Precision Medicines develops drugs to treat epilepsy and other central nervous system disorders. Its capitalization is a risky bet on its genetic approach to discovering new treatments.
Book value capitalization of the company, segment and market as a whole
PRAX - Book value capitalization of the company Praxis Precision Medicines
Praxis Precision Medicines is a capital asset for the fight against diseases of the central nervous system. The company's book value at the R&D stage consists of financial reserves. These assets are used for clinical trials of drugs for conditions such as epilepsy and depression.
PRAX - Share of the company's book capitalization Praxis Precision Medicines within the market segment - Neuro
Praxis Precision Medicines, a clinical-stage biopharmaceutical company, focuses on neuroscience. Its stake in the sector consists of R&D laboratories. Currently, the company is building its scientific foundation, and its value lies in the potential of its investigational drugs.
Market segment balance sheet capitalization - Neuro
Praxis Precision Medicines develops drugs for the treatment of central nervous system diseases. Pharmaceuticals, as the graph shows, are knowledge- and capital-intensive. Praxis is an R&D company, its capital being intellectual property and clinical trial data.
Book value of all companies included in the broad market index - GURU.Markets
Praxis Precision Medicines is a biopharmaceutical company focused on treating central nervous system disorders, such as epilepsy. Its book value is the capital it invests in its clinical programs to test new treatment approaches.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Praxis Precision Medicines
Praxis Precision Medicines is a biotech company. Its market capitalization is close to its book value (primarily cash), suggesting the market is currently taking a wait-and-see approach to the success of its clinical trials.
Market to book capitalization ratio in a market segment - Neuro
Praxis Precision Medicines develops drugs for the treatment of central nervous system diseases. Like other development-stage biotech companies, its valuation is based on its scientific potential. The chart demonstrates the high market valuation of its developments compared to its meager tangible assets.
Market to book capitalization ratio for the market as a whole
Praxis Precision Medicines is a biopharmaceutical company specializing in the treatment of neurological disorders by modulating ion channels in the brain. Compared to average market valuations shown in this chart, its high premium is speculative and based on the potential of its scientific approach to treating epilepsy and other conditions.
Debts of the company, segment and market as a whole
PRAX - Company debts Praxis Precision Medicines
Praxis Precision Medicines is a biotech company focused on treating neurological disorders. Being in clinical development, the company has no sales revenue and relies entirely on raised capital. This chart shows how the company funds its expensive research and development in one of the most complex areas of medicine.
Market segment debts - Neuro
Praxis Precision Medicines is a clinical-stage biopharmaceutical company specializing in diseases of the central nervous system. Its expensive and time-consuming research is funded entirely by equity capital. This chart reflects its current financial position and the headroom it has for continued development.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Praxis Precision Medicines
Praxis Precision Medicines is a biopharmaceutical company developing drugs for neurological disorders. This chart shows its financial structure. For a company in the R&D stage with no revenue, debt is a critical risk. It reflects the company's reliance on the success of clinical trials, failure of which could be fatal.
Market segment debt to market segment book capitalization - Neuro
Praxis Precision Medicines is a biopharmaceutical company focused on treating neurological disorders. Developing drugs for the central nervous system is one of the most complex and expensive processes in the industry. This chart shows the overall debt burden in the biotech sector. It provides insight into how Praxis finances its long-term and risky clinical programs.
Debt to book value of all companies in the market
Praxis Precision Medicines is a biopharmaceutical company developing drugs for neurological disorders. Being in clinical development, it does not generate revenue and relies on investors. This chart shows that, given the current credit environment, raising equity rather than debt is practically the only financing option for Praxis.
P/E of the company, segment and market as a whole
P/E - Praxis Precision Medicines
For Praxis Precision Medicines, a biotech focused on neuroscience, the P/E ratio is not a meaningful metric. The company has no profitable products. Its valuation on this chart is arbitrary and does not reflect its true value, which depends entirely on the success or failure of its clinical trials.
P/E of the market segment - Neuro
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, such as epilepsy and depression. This chart shows the average valuation for the biotech sector, reflecting investor sentiment toward the complex but potentially vast CNS disease market.
P/E of the market as a whole
Praxis Precision Medicines is a biopharmaceutical company specializing in the treatment of neurological disorders. Its valuation is a pure bet on the success of its clinical programs. The overall market sentiment reflected in this chart is completely irrelevant to the company, whose fate depends on the effectiveness and safety of its experimental drugs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Praxis Precision Medicines
Praxis Precision Medicines is a biopharmaceutical company focused on treating central nervous system disorders such as epilepsy and depression. Its value is based on the potential of its scientific developments. This chart reflects investors' confidence in the success of the company's clinical programs, assessing its current value based on projected future revenues.
%20P%2FE%20Praxis%20Precision%20Medicines&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Praxis-Precision-Medicines&v=1772658468686 "Chart of the company's future (projected) P/E Praxis Precision Medicines")
Future (projected) P/E of the market segment - Neuro
Praxis Precision Medicines is a biopharmaceutical company developing treatments for central nervous system disorders such as epilepsy and depression. The chart reflects average profitability expectations for the biotech sector. Praxis's position relative to this benchmark reflects investors' bet on their scientific approach to restoring neuronal balance in the brain.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772658468737 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Praxis Precision Medicines is a biopharmaceutical company focused on treating diseases of the central nervous system. The company's valuation is based on the hopes for future drugs. This chart, showing the overall market appetite for risk, determines how easy or difficult it is for companies like Praxis to raise funds for lengthy and expensive research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772658468780 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Praxis Precision Medicines
Praxis Precision Medicines is a biotech company developing drugs for the treatment of central nervous system disorders, such as epilepsy and depression. Its current financial schedule is dominated by expenses for extensive clinical trials. Profitability is only possible after the successful launch of its drugs.
Profit of companies in the market segment - Neuro
Praxis Precision Medicines is a biopharmaceutical company focused on developing genetically based treatments for neurological disorders such as epilepsy and depression. Its future depends on the success of clinical trials. This chart shows the total revenue in its sector, illustrating the overall investment attractiveness and progress in the treatment of CNS diseases.
Overall market profit
Praxis Precision Medicines develops drugs for the treatment of central nervous system diseases. This is a capital-intensive process dependent on external funding. Overall market conditions, reflected in corporate earnings trends, influence investor willingness to invest in long-term, high-risk biotech projects, which is critical for Praxis.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Praxis Precision Medicines
Praxis Precision Medicines is a biopharmaceutical company focused on treating central nervous system disorders, such as epilepsy. Future profits depend on the success of clinical trials. This chart shows analysts' speculative expectations regarding the potential of Praxis' neuroscience developments.
%20profit%20of%20the%20company%20Praxis%20Precision%20Medicines&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Praxis-Precision-Medicines&v=1772658468999 "Graph of future (projected) profit of the company Praxis Precision Medicines")
Future (predicted) profit of companies in the market segment - Neuro
Praxis Precision Medicines is a biotech company developing drugs to treat neurological disorders such as epilepsy and depression. Its future depends entirely on clinical trial results and regulatory approval. This chart reflects profitability forecasts for the entire biotech sector, providing context for assessing Praxis's high potential and risks.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772658469014 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Praxis Precision Medicines is a biopharmaceutical company focused on treating diseases of the central nervous system. Its trajectory is entirely dependent on scientific developments and clinical trial results. The overall economic indicators presented in this chart are not directly related to its operating performance.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772658469030 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Praxis Precision Medicines
Praxis Precision Medicines is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders. Despite minimal operating revenue, this chart demonstrates a high assessment of its scientific potential. Fluctuations in this indicator are a direct response to the clinical trial results of its experimental drugs.
P/S market segment - Neuro
Praxis Precision Medicines is a biopharmaceutical company developing treatments for central nervous system disorders such as epilepsy and depression. Future revenue depends on the success of its drugs. This chart for the neuroscience sector compares investor expectations for Praxis's scientific platform with those of other companies in this complex field.
P/S of the market as a whole
Praxis Precision Medicines is a biopharmaceutical company focused on developing treatments for neurological disorders such as epilepsy and depression. The company uses a genetic approach to create targeted therapies. This market revenue valuation chart helps understand how high investor expectations are for potential breakthroughs in brain disease treatment.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Praxis Precision Medicines
Praxis Precision Medicines is a biopharmaceutical company focused on developing treatments for neurological disorders such as epilepsy and depression. This chart shows how the market views the scientific potential of its developments. It reflects investors' confidence that the company's drug candidates will successfully complete clinical trials and reach the market.
%20P%2FS%20Praxis%20Precision%20Medicines&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Praxis-Precision-Medicines&v=1772658469168 "The graph of the company's future (projected) P/S Praxis Precision Medicines")
Future (projected) P/S of the market segment - Neuro
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, such as epilepsy and depression, by targeting the genetic causes of neuronal imbalances. The company's valuation is based on investors' confidence in its scientific approach and the potential of its drug candidates.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772658469193 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Praxis Precision Medicines is a biotech company focused on treating neurological disorders. Its value is based on the potential of its developments. In the overall revenue growth picture illustrated by the chart, Praxis represents a sector where market capitalization reflects future scientific revenue.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772658469218 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Praxis Precision Medicines
Praxis Precision Medicines is a biotech company developing treatments for central nervous system (CNS) disorders, such as epilepsy and depression. Being in the clinical stage, it has no commercial revenue. Any revenue shown in the chart likely comes from funding from partners.
Sales of companies in the market segment - Neuro
Praxis Precision Medicines (PRAX) is a biopharmaceutical company developing treatments for neurological and central nervous system disorders, including epilepsy and depression. It uses genetic data to create targeted therapies. This chart shows revenue from the company's neuroscience segment, where Praxis's scientific approach could lead to breakthrough drugs.
Overall market sales
Praxis Precision Medicines is a biopharmaceutical company developing treatments for diseases of the central nervous system. Its success depends on scientific breakthroughs, but its funding depends on market conditions. This chart, reflecting overall economic confidence, influences investors' willingness to invest in long-term and risky biotech projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Praxis Precision Medicines
Praxis Precision Medicines is a biotechnology company focused on developing drugs for the treatment of central nervous system disorders, such as epilepsy and depression. Its future revenue depends on the success of clinical trials. This chart reflects analyst forecasts, which are estimates of the likelihood of commercialization of their developments and the size of the target market.
%20sales%20of%20the%20company%20Praxis%20Precision%20Medicines&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Praxis-Precision-Medicines&v=1772658469331 "Schedule of future (projected) sales of the company Praxis Precision Medicines")
Future (projected) sales of companies in the market segment - Neuro
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on treating central nervous system (CNS) disorders. This graph shows the potential future revenue from their pipeline. This is an analyst's perspective on the commercial prospects of their approaches to treating epilepsy and other conditions.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772658469353 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Praxis Precision Medicines is a clinical-stage biotech company focused on developing treatments for central nervous system disorders, such as epilepsy. Its valuation is dependent on scientific results. This graph, reflecting market sentiment, influences the availability of capital for funding long-term and risky neuroscience research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772658469533 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Praxis Precision Medicines
Praxis Precision Medicines is a biopharmaceutical company focused on developing treatments for central nervous system disorders, such as epilepsy and depression. While in clinical development, the company incurs significant expenses. The chart shows current profitability, which is an investment in potential future commercial success.
Market segment marginality - Neuro
Praxis Precision Medicines is a biopharmaceutical company developing treatments for central nervous system disorders such as epilepsy and depression. This chart reflects its operating expenses during clinical trials. This trend is important for assessing cost control during the development of new drugs.
Market marginality as a whole
Praxis Precision Medicines is a clinical-stage biotech company focused on treating neurological disorders. It relies entirely on investor capital. This total return chart reflects the market's risk appetite. During periods of high profitability and optimism, investors are more inclined to fund long-term scientific projects.
Employees in the company, segment and market as a whole
Number of employees in the company Praxis Precision Medicines
Praxis Precision Medicines is a biopharmaceutical company developing treatments for neurological disorders. Its team consists of scientists and clinicians. The growth in staff, which can be seen in this chart, is directly related to the advancement of its drug candidates through the costly and complex stages of clinical trials.
Share of the company's employees Praxis Precision Medicines within the market segment - Neuro
Praxis Precision Medicines is a biotechnology company developing treatments for diseases of the central nervous system. During clinical trials, its most important resource is its scientific and medical team. This chart demonstrates the scale of the human capital the company is investing in solving the most complex problems in neurology and psychiatry.
Number of employees in the market segment - Neuro
Praxis Precision Medicines develops treatments for neurological disorders, particularly epilepsy. This chart, showing employment in neuroscience, illustrates the scale and complexity of brain research. For Praxis, the growing number of scientists in this field means accelerated discovery, creating both opportunities for breakthroughs and intense competition for talent and patents.
Number of employees in the market as a whole
Praxis Precision Medicines is a biopharmaceutical company focused on disorders of the central nervous system. Its hiring of researchers and clinical staff is driven by scientific advancement, not economic cycles. The company seeks highly specialized talent to address complex brain diseases.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Praxis Precision Medicines (PRAX)
Praxis Precision Medicines is a biopharmaceutical company developing treatments for neurological disorders such as epilepsy. Its entire capital comes from research and development. This metric demonstrates the enormous value the market places on the potential of its drugs, developed by a small team of scientists and physician researchers.
%20of%20the%20company%20Praxis%20Precision%20Medicines%20(PRAX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Praxis-Precision-Medicines-PRAX&v=1772658469682 "Chart of market capitalization per employee (in thousands of dollars) of the company Praxis Precision Medicines (PRAX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Praxis Precision Medicines is a biopharmaceutical company focused on treating diseases of the central nervous system. Its value is based on the potential of its scientific developments. This chart shows the high future value the market places on the research of each scientist who has the potential to create a breakthrough drug in neurology.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772658469757 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Praxis Precision Medicines is a biopharmaceutical company developing treatments for neurological disorders. The chart reflects its scientific potential. The company's entire value is derived from its research and scientific team. This indicator demonstrates how investors assess the company's development prospects based on each member of this elite scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772658469829 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Praxis Precision Medicines (PRAX)
Praxis Precision Medicines is a biotech company focused on treating diseases of the central nervous system (CNS). The company is in clinical development. This chart likely shows negative values—the "burn" of capital per scientist. This reflects the investment in epilepsy and other disorders.
%20Chart%20Praxis%20Precision%20Medicines%20(PRAX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Praxis-Precision-Medicines-PRAX&v=1772658469908 "Company Profit Per Employee (in thousands of dollars) Chart Praxis Precision Medicines (PRAX)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Praxis Precision Medicines is a biopharmaceutical company specializing in the treatment of neurological disorders (e.g., epilepsy). It is a clinical-stage R&D company. This loss per employee reflects the high cost of conducting complex clinical trials in neurology.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772658469929 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Praxis Precision Medicines is a biotech company specializing in the treatment of neurological disorders such as epilepsy. The company is in clinical development. Its entire staff consists of scientists and physicians engaged in R&D. There is no profit. This chart is important to understand that in neurological biotech, employees are a cost center, creating future intellectual property.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772658469967 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Praxis Precision Medicines (PRAX)
Praxis Precision Medicines is a biopharmaceutical company focused on the treatment of neurological disorders. Being in the clinical stage, it does not yet have commercial products. This graph would show zero revenue, which is typical for R&D companies whose value is determined by the potential of their scientific developments in the field of CNS diseases.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Praxis-Precision-Medicines-PRAX&v=1772658469996 "Sales chart per company employee Praxis Precision Medicines (PRAX)")
Sales per employee in the market segment - Neuro
Praxis Precision Medicines (PRAX) is a biotech company developing treatments for central nervous system (CNS) disorders, such as epilepsy. This chart shows the average revenue per employee in the sector. For a company in the R&D stage, this is important for assessing the efficiency of capital and personnel utilization compared to competitors.
Sales per employee for the market as a whole
Praxis Precision Medicines (PRAX) is a biotech company developing drugs for neurological disorders such as epilepsy and depression. The company is in the clinical stage, meaning its revenue is minimal or nonexistent. This metric reflects the company's investment in R&D and scientific personnel. Investors look to this metric in anticipation of future breakthroughs and commercialization of their developments.
Short shares by company, segment and market as a whole
Shares shorted by company Praxis Precision Medicines (PRAX)
Praxis Precision Medicines (PRAX) is a clinical-stage biotech company specializing in the treatment of neurological disorders such as epilepsy and depression. This chart shows bearish sentiment. The high number of short positions is typical for biotech and reflects investor doubts about the success of clinical trials. Failures in neuroscience are particularly frequent and costly. (342)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Praxis-Precision-Medicines-PRAX&v=1772658470066 "Short Shares Chart for the Company Praxis Precision Medicines (PRAX)")
Shares shorted by market segment - Neuro
Praxis is a biotech company focused on treating neurological disorders (epilepsy, essential tremor) by "balancing" brain function. This chart reflects the overall sentiment in the sector, reflecting investor skepticism toward biotech companies working in the highly complex field of neuroscience.
Shares shorted by the overall market
Praxis Precision Medicines (PRAX) is a biotech company focused on treating complex neurological disorders. Brain drug development is one of the most complex and expensive areas of medicine. This chart illustrates the market's doubts about the success of their developments. Skeptics are betting that clinical trials will not confirm the drugs' effectiveness or that the company will be unable to commercialize its discoveries.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Praxis Precision Medicines (PRAX)
Praxis Precision Medicines is a biotech company focused on complex brain diseases (CNS). Stocks in this sector are pure bets on science. This chart measures the strength of investor hope. It shows when the stock is "overbought" on anticipation of trial data or "oversold" to the bottom after the announcement of failure.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Praxis-Precision-Medicines-PRAX&v=1772658470271 "RSI 14 indicator chart for the company's stock Praxis Precision Medicines (PRAX)")
RSI 14 Market Segment - Neuro
Praxis Precision Medicines is a biopharmaceutical company specializing in diseases of the central nervous system (CNS). They are developing treatments for epilepsy, depression, and movement disorders. This chart reflects the overall sentiment in the biotech sector. It helps assess how the market views this speculative industry as a whole, and how Praxis compares to that.
RSI 14 for the overall market
Praxis Precision (PRAX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PRAX (Praxis Precision Medicines)
Praxis Precision Medicines is a biopharmaceutical company focused on developing treatments for neurological disorders such as epilepsy and movement disorders. This chart displays the analyst consensus view: their average price target for Praxis shares, which depends on R&D.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PRAX-Praxis-Precision-Medicines&v=1772658470306 "A chart showing analyst consensus forecasts for the expected stock price. PRAX (Praxis Precision Medicines)")
The difference between the consensus estimate and the actual stock price PRAX (Praxis Precision Medicines)
Praxis Precision Medicines is a clinical-stage biotech company focused on developing drugs for the treatment of severe neurological disorders, primarily epilepsy and movement disorders. This chart reflects analysts' speculative expectations for their R&D platform and clinical data.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PRAX-Praxis-Precision-Medicines&v=1772658470342 "A chart showing the difference between the consensus forecast and the actual stock price. PRAX (Praxis Precision Medicines)")
Analyst consensus forecast for stock prices by market segment - Neuro
Praxis Precision Medicines is a biotech company focused on developing drugs for severe neurological disorders (epilepsy, essential tremor) using a genetic approach. This chart shows analysts' overall expectations for the neuroscience sector. It reflects whether experts believe breakthroughs in brain disease treatments are possible.
Analysts' consensus forecast for the overall market share price
Praxis Precision Medicines is a biotech company specializing in developing treatments for central nervous system (CNS) disorders, such as epilepsy and depression. This chart shows overall risk appetite. For Praxis, which operates in the complex field of neuroscience, overall market optimism is critical to funding lengthy and expensive clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Praxis Precision Medicines
Praxis Precision Medicines is a biotech company focused on treating severe neurological disorders. Their R&D platform targets genetic forms of epilepsy and other CNS diseases using precision science. This graph is an assessment of their complex pipeline. It reflects investors' faith in their science and expectations for clinical data in one of the most challenging areas of medicine.
AKIMA Market Segment Index - Neuro
Praxis Precision (PRAX) is a clinical-stage biotech focused on neuroscience; the company develops innovative drugs for the treatment of rare CNS disorders (e.g., epilepsy). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this niche (CNS) R&D focus (PRAX) differentiate it from the average pharma company?
The AKIM Index for the overall market
Praxis Precision Medicines is a biotech company developing genetically based treatments for central nervous system disorders (epilepsy). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this research company, targeting complex neurological disorders, compares to overall economic trends.
